Cargando…
Electrical neurostimulation in glaucoma with progressive vision loss
BACKGROUND: The retrospective study provides real-world evidence for long-term clinical efficacy of electrical optic nerve stimulation (ONS) in glaucoma with progressive vision loss. METHODS: Seventy glaucoma patients (45 to 86 y) with progressive vision loss despite therapeutic reduction of intraoc...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969331/ https://www.ncbi.nlm.nih.gov/pubmed/35361287 http://dx.doi.org/10.1186/s42234-022-00089-9 |
_version_ | 1784679224412471296 |
---|---|
author | Erb, Carl Eckert, Sophie Gindorf, Pia Köhler, Martin Köhler, Thomas Neuhann, Lukas Neuhann, Thomas Salzmann, Nadja Schmickler, Stefanie Ellrich, Jens |
author_facet | Erb, Carl Eckert, Sophie Gindorf, Pia Köhler, Martin Köhler, Thomas Neuhann, Lukas Neuhann, Thomas Salzmann, Nadja Schmickler, Stefanie Ellrich, Jens |
author_sort | Erb, Carl |
collection | PubMed |
description | BACKGROUND: The retrospective study provides real-world evidence for long-term clinical efficacy of electrical optic nerve stimulation (ONS) in glaucoma with progressive vision loss. METHODS: Seventy glaucoma patients (45 to 86 y) with progressive vision loss despite therapeutic reduction of intraocular pressure (IOP) underwent electrical ONS. Closed eyes were separately stimulated by bipolar rectangular pulses with stimulus intensities up to 1.2 mA sufficient to provoke phosphenes. Ten daily stimulation sessions within 2 weeks lasted about 80 min each. Right before ONS at baseline (PRE), vision loss was documented by static threshold perimetry and compared to the same assessment approximately 1 year afterwards (POST). Mean defect (MD) was defined as primary outcome parameter. Perimetries with a reliability factor (RF) of max. 20% were considered. RESULTS: Perimetry follow-up of 101 eyes in 70 patients fulfilled the criterion of a max. 20% RF. Follow-up was performed on average 362.2 days after ONS. MD significantly decreased from PRE 14.0 dB (median) to POST 13.4 dB (p < 0.01). 64 eyes in 49 patients showed constant or reduced MD as compared to baseline (PRE 13.4 dB vs. POST 11.2 dB). In 37 eyes of 30 patients, MD increased from PRE 14.9 dB to POST 15.6 dB. CONCLUSIONS: Innovative treatments that preserve visual function through mechanisms other than lowering IOP are required for glaucoma with progressive vision loss. The present long-term data document progression halt in more than 63% of affected eyes after ONS and, thus, extend existing evidence from clinical trials. |
format | Online Article Text |
id | pubmed-8969331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89693312022-04-01 Electrical neurostimulation in glaucoma with progressive vision loss Erb, Carl Eckert, Sophie Gindorf, Pia Köhler, Martin Köhler, Thomas Neuhann, Lukas Neuhann, Thomas Salzmann, Nadja Schmickler, Stefanie Ellrich, Jens Bioelectron Med Research Article BACKGROUND: The retrospective study provides real-world evidence for long-term clinical efficacy of electrical optic nerve stimulation (ONS) in glaucoma with progressive vision loss. METHODS: Seventy glaucoma patients (45 to 86 y) with progressive vision loss despite therapeutic reduction of intraocular pressure (IOP) underwent electrical ONS. Closed eyes were separately stimulated by bipolar rectangular pulses with stimulus intensities up to 1.2 mA sufficient to provoke phosphenes. Ten daily stimulation sessions within 2 weeks lasted about 80 min each. Right before ONS at baseline (PRE), vision loss was documented by static threshold perimetry and compared to the same assessment approximately 1 year afterwards (POST). Mean defect (MD) was defined as primary outcome parameter. Perimetries with a reliability factor (RF) of max. 20% were considered. RESULTS: Perimetry follow-up of 101 eyes in 70 patients fulfilled the criterion of a max. 20% RF. Follow-up was performed on average 362.2 days after ONS. MD significantly decreased from PRE 14.0 dB (median) to POST 13.4 dB (p < 0.01). 64 eyes in 49 patients showed constant or reduced MD as compared to baseline (PRE 13.4 dB vs. POST 11.2 dB). In 37 eyes of 30 patients, MD increased from PRE 14.9 dB to POST 15.6 dB. CONCLUSIONS: Innovative treatments that preserve visual function through mechanisms other than lowering IOP are required for glaucoma with progressive vision loss. The present long-term data document progression halt in more than 63% of affected eyes after ONS and, thus, extend existing evidence from clinical trials. BioMed Central 2022-03-31 /pmc/articles/PMC8969331/ /pubmed/35361287 http://dx.doi.org/10.1186/s42234-022-00089-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Erb, Carl Eckert, Sophie Gindorf, Pia Köhler, Martin Köhler, Thomas Neuhann, Lukas Neuhann, Thomas Salzmann, Nadja Schmickler, Stefanie Ellrich, Jens Electrical neurostimulation in glaucoma with progressive vision loss |
title | Electrical neurostimulation in glaucoma with progressive vision loss |
title_full | Electrical neurostimulation in glaucoma with progressive vision loss |
title_fullStr | Electrical neurostimulation in glaucoma with progressive vision loss |
title_full_unstemmed | Electrical neurostimulation in glaucoma with progressive vision loss |
title_short | Electrical neurostimulation in glaucoma with progressive vision loss |
title_sort | electrical neurostimulation in glaucoma with progressive vision loss |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969331/ https://www.ncbi.nlm.nih.gov/pubmed/35361287 http://dx.doi.org/10.1186/s42234-022-00089-9 |
work_keys_str_mv | AT erbcarl electricalneurostimulationinglaucomawithprogressivevisionloss AT eckertsophie electricalneurostimulationinglaucomawithprogressivevisionloss AT gindorfpia electricalneurostimulationinglaucomawithprogressivevisionloss AT kohlermartin electricalneurostimulationinglaucomawithprogressivevisionloss AT kohlerthomas electricalneurostimulationinglaucomawithprogressivevisionloss AT neuhannlukas electricalneurostimulationinglaucomawithprogressivevisionloss AT neuhannthomas electricalneurostimulationinglaucomawithprogressivevisionloss AT salzmannnadja electricalneurostimulationinglaucomawithprogressivevisionloss AT schmicklerstefanie electricalneurostimulationinglaucomawithprogressivevisionloss AT ellrichjens electricalneurostimulationinglaucomawithprogressivevisionloss |